drugset / Trial / NCT06934057
Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The goal of the study is to describe real-life use and exposition to nivolumab-cabozantinib among older patients with metastatic clear-cell renal cell cancer
Timeline
- Start
- 2025-05-16
- Primary completion
- 2028-04
- Completion
- 2028-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | 40 mg | Oral |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |